Literature DB >> 28848067

Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.

Yumi Nakayama1, Jolanta Kosek1, Lori Capone1, Eun Mi Hur1, Peter H Schafer1, Garth E Ringheim2.   

Abstract

BAFF is a B cell survival and maturation factor implicated in the pathogenesis of systemic lupus erythematosus (SLE). In this in vitro study, we describe that soluble BAFF in combination with IL-2 and IL-21 is a T cell contact-independent inducer of human B cell proliferation, plasmablast differentiation, and IgG secretion from circulating CD27+ memory and memory-like CD27-IgD- double-negative (DN) B cells, but not CD27-IgD+ naive B cells. In contrast, soluble CD40L in combination with IL-2 and IL-21 induces these activities in both memory and naive B cells. Blood from healthy donors and SLE patients have similar circulating levels of IL-2, whereas SLE patients exhibit elevated BAFF and DN B cells and reduced IL-21. B cell differentiation transcription factors in memory, DN, and naive B cells in SLE show elevated levels of Aiolos, whereas Ikaros levels are unchanged. Treatment with CC-220, a modulator of the cullin ring ligase 4-cereblon E3 ubiquitin ligase complex, reduces Aiolos and Ikaros protein levels and BAFF- and CD40L-induced proliferation, plasmablast differentiation, and IgG secretion. The observation that the soluble factors BAFF, IL-2, and IL-21 induce memory and DN B cell activation and differentiation has implications for extrafollicular plasmablast development within inflamed tissue. Inhibition of B cell plasmablast differentiation by reduction of Aiolos and Ikaros may have utility in the treatment of SLE, where elevated levels of BAFF and Aiolos may prime CD27+ memory and DN memory-like B cells to become Ab-producing plasmablasts in the presence of BAFF and proinflammatory cytokines.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28848067      PMCID: PMC5602157          DOI: 10.4049/jimmunol.1601725

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  131 in total

Review 1.  Plasma cells: finding new light at the end of B cell development.

Authors:  K L Calame
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

Review 2.  The coming of age of the immunoglobulin J chain.

Authors:  M E Koshland
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

3.  BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.

Authors:  Viktor Roschke; Svetlana Sosnovtseva; Christopher D Ward; June S Hong; Rodger Smith; Vivian Albert; William Stohl; Kevin P Baker; Stephen Ullrich; Bernardetta Nardelli; David M Hilbert; Thi-Sau Migone
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

4.  [Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance].

Authors:  Xiao-Fei Wang; Shuang-Long Yuan; Li Jiang; Xiao-Li Zhang; Shu-Fan Li; Yun Guo; Chun-Ling Wu; Juan-Juan Chen
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2007-11

Review 5.  The role of IL-21 in regulating B-cell function in health and disease.

Authors:  Rachel Ettinger; Stefan Kuchen; Peter E Lipsky
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

6.  Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue.

Authors:  Vladimir M Liarski; Natalya Kaverina; Anthony Chang; Daniel Brandt; Denisse Yanez; Lauren Talasnik; Gianluca Carlesso; Ronald Herbst; Tammy O Utset; Christine Labno; Yahui Peng; Yulei Jiang; Maryellen L Giger; Marcus R Clark
Journal:  Sci Transl Med       Date:  2014-04-02       Impact factor: 17.956

7.  B cell biomarkers of rituximab responses in systemic lupus erythematosus.

Authors:  Edward M Vital; Shouvik Dass; Maya H Buch; Karen Henshaw; Colin T Pease; Michael F Martin; Frederique Ponchel; Andrew C Rawstron; Paul Emery
Journal:  Arthritis Rheum       Date:  2011-10

8.  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Authors:  Susan Manzi; Jorge Sánchez-Guerrero; Joan T Merrill; Richard Furie; Dafna Gladman; Sandra V Navarra; Ellen M Ginzler; David P D'Cruz; Andrea Doria; Simon Cooper; Z John Zhong; Douglas Hough; William Freimuth; Michelle A Petri
Journal:  Ann Rheum Dis       Date:  2012-05-01       Impact factor: 19.103

9.  Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production.

Authors:  Sharon A Chung; Kimberly E Taylor; Robert R Graham; Joanne Nititham; Annette T Lee; Ward A Ortmann; Chaim O Jacob; Marta E Alarcón-Riquelme; Betty P Tsao; John B Harley; Patrick M Gaffney; Kathy L Moser; Michelle Petri; F Yesim Demirci; M Ilyas Kamboh; Susan Manzi; Peter K Gregersen; Carl D Langefeld; Timothy W Behrens; Lindsey A Criswell
Journal:  PLoS Genet       Date:  2011-03-03       Impact factor: 5.917

Review 10.  Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway.

Authors:  Shereen Oon; Nicholas J Wilson; Ian Wicks
Journal:  Clin Transl Immunology       Date:  2016-05-13
View more
  14 in total

Review 1.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

Review 2.  Cereblon: promise and challenges for combating human diseases.

Authors:  Hyoung Kyu Kim; Jung Eun Seol; Sang Woo Ahn; Seungje Jeon; Chul-Seung Park; Jin Han
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 3.657

3.  Biological impact of iberdomide in patients with active systemic lupus erythematosus.

Authors:  Peter E Lipsky; Ronald van Vollenhoven; Thomas Dörner; Victoria P Werth; Joan T Merrill; Richard Furie; Milan Petronijevic; Benito Velasco Zamora; Maria Majdan; Fedra Irazoque-Palazuelos; Robert Terbrueggen; Nikolay Delev; Michael Weiswasser; Shimon Korish; Mark Stern; Sarah Hersey; Ying Ye; Allison Gaudy; Zhaohui Liu; Robert Gagnon; Shaojun Tang; Peter H Schafer
Journal:  Ann Rheum Dis       Date:  2022-04-27       Impact factor: 27.973

4.  Endothelial expression of human amyloid precursor protein leads to amyloid β in the blood and induces cerebral amyloid angiopathy in knock-in mice.

Authors:  Yuriko Tachida; Saori Miura; Yui Muto; Hiroyuki Takuwa; Naruhiko Sahara; Akihiro Shindo; Yukio Matsuba; Takashi Saito; Naoyuki Taniguchi; Yasushi Kawaguchi; Hidekazu Tomimoto; Takaomi Saido; Shinobu Kitazume
Journal:  J Biol Chem       Date:  2022-03-31       Impact factor: 5.486

Review 5.  Abnormal B Cell Development in Systemic Lupus Erythematosus: What the Genetics Tell Us.

Authors:  Sarah Karrar; Deborah S Cunninghame Graham
Journal:  Arthritis Rheumatol       Date:  2018-02-22       Impact factor: 10.995

6.  Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.

Authors:  Peter H Schafer; Ying Ye; Lei Wu; Jolanta Kosek; Garth Ringheim; Zhihong Yang; Liangang Liu; Michael Thomas; Maria Palmisano; Rajesh Chopra
Journal:  Ann Rheum Dis       Date:  2018-06-26       Impact factor: 19.103

7.  UBE2G1 governs the destruction of cereblon neomorphic substrates.

Authors:  Stephanie Weng; Mary Matyskiela; Gang Lu; Xinde Zheng; Wei Fang; Scott Wood; Christine Surka; Reina Mizukoshi; Chin-Chun Lu; Derek Mendy; In Sock Jang; Kai Wang; Mathieu Marella; Suzana Couto; Brian Cathers; James Carmichael; Philip Chamberlain; Mark Rolfe
Journal:  Elife       Date:  2018-09-20       Impact factor: 8.140

8.  Trans-Ancestral Fine-Mapping and Epigenetic Annotation as Tools to Delineate Functionally Relevant Risk Alleles at IKZF1 and IKZF3 in Systemic Lupus Erythematosus.

Authors:  Timothy J Vyse; Deborah S Cunninghame Graham
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

9.  CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.

Authors:  Christine Surka; Liqing Jin; Nathan Mbong; Chin-Chun Lu; In Sock Jang; Emily Rychak; Derek Mendy; Thomas Clayton; Elizabeth Tindall; Christy Hsu; Celia Fontanillo; Eileen Tran; Adrian Contreras; Stanley W K Ng; Mary Matyskiela; Kai Wang; Philip Chamberlain; Brian Cathers; James Carmichael; Joshua Hansen; Jean C Y Wang; Mark D Minden; Jinhong Fan; Daniel W Pierce; Michael Pourdehnad; Mark Rolfe; Antonia Lopez-Girona; John E Dick; Gang Lu
Journal:  Blood       Date:  2021-02-04       Impact factor: 25.476

10.  First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.

Authors:  Ying Ye; Allison Gaudy; Peter Schafer; Michael Thomas; Daniel Weiss; Nianhang Chen; Liangang Liu; Yongjun Xue; Leon Carayannopoulos; Maria Palmisano
Journal:  Clin Pharmacol Drug Dev       Date:  2020-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.